Get Latest Tori News Alert!
Enter your email below.

Delivered by FeedBurner





Hot Stories
Recent Stories

ACE-031 Peptide: Muscle Cells

Posted by Thandiubani on Wed 28th Feb, 2024 - tori.ng

Investigations purport that peptide ACE-031 may include a recombinant fusion protein that joins an ActRIIB receptor with an antibody in mice.

Studies have examined soluble activin receptor type IIB (ActRIIB) proteins like ACE 031 for their potential impact in biological activities and IgG1-Fc. Research indicates that the ACE-031 peptide may control muscle size in mice by blocking the natural production of myostatin, a protein secreted in the muscles that act as a growth factor, and other ligands that restrict muscle development.

ACE-031 Peptide: What is it?

Investigations purport that peptide ACE-031 may include a recombinant fusion protein that joins an ActRIIB receptor with an antibody in mice. As the off signal is reduced, muscle synthesis stops, strengthening muscles. Findings have implied that ACE-031 may inhibit the secretion of these ligands, leading to enhanced muscle growth in the mice examined. 
 
Numerous animal studies have indicated that ACE-031 might considerably enhance muscular growth and strength. Research also suggests that it may stave against neuromuscular diseases and muscle atrophy. Although ACE-031 protein has not been licensed for human ingestion, clinical studies in the context of neuromuscular diseases and enhancing muscle mass indicate some potential.

ACE-031 Peptide: Muscle Cells

Chief Executive Officer John Knopf, Ph.D. of Acceleron, suggested, "ACE-031 holds great potential as a treatment for mice models of neuromuscular illnesses including muscular dystrophy and amyotrophic lateral sclerosis (ALS)". 
 
In disorders like amyotrophic lateral sclerosis and muscular dystrophy, muscle mass degeneration is the direct cause of mortality in mice, highlighting the importance of muscle cells. The possible function of ACE-031 in halting muscular atrophy is becoming increasingly interesting to researchers. 
 
New research theorizes that myostatin-blocking substances, such as ACE 031, may mitigate the effects of renal failure and cancer cachexia on muscle and contractile force loss in animals. They have also been hypothesized to stimulate insulin sensitivity, reduce inflammation, decrease fat mass, and improve bone repair and mineralization, among other possible properties. 
 
The potential of ACE 031 on muscle hypertrophy in mice was indicated to be independent of fiber-type expression.

ACE-031 Peptide: Neuromuscular Studies 

The biopharmaceutical company Acceleron Pharma, Inc. has lately announced the results of their Phase 1 single-concentration clinical trial for ACE-031, which suggested that the peptide might increase lean body mass. The trial was designed to encourage the growth of various cells and tissues, such as muscle, red blood cells, and bone. 
 
The Chief Medical Officer of Acceleron, Matthew Shermice, M.D., expressed his excitement over the positive data and biological potential speculated in the ACE-031 Phase 1 clinical trial. The findings implied that several indicators for bone formation and fat composition appeared elevated, and ACE-031 seemed to have caused concentration-dependent, fast, and sustained gains in lean body mass and muscle volume. "We are excited to continue developing ACE-031 to aid neuromuscular disorders, and based on these findings, we have begun Phase 1 multiple-concentration research."

ACE-031 Peptide: Properties

Multiple studies have evaluated its potential in the context of various illnesses, including those causing muscular atrophy. Many studies suggest it may effectively block chemicals inhibiting muscle development and contractile force. 
 
ACE-031 peptides are highly sought after by scientists throughout the globe. They are interested in delving more into this intriguing peptide and its potential research applications in murine models. Animal studies have purported that ACE-031 may exert several positive potential impacts, including but not limited to improving muscular development, fat loss, bone strength, physical performance, and blood flow. 
 
Researchers now have a possible research tool in the shape of ACE-031, a soluble version of the activin receptor type IIB (ActRIIB), to investigate the function of the activin/myostatin pathway in the process of muscle development and growth. Among the many properties this peptide has been hypothesized to offer over competing research tools are its high affinity for activin and myostatin, its strong inhibitory action on these growth factors, and its possible use in studying illnesses and disorders characterized by muscle wasting. 

ACE-031 Peptide: Research Studies

When tested on animal models of muscular atrophy and wasting illnesses, ACE-031 suggested encouraging results. Research on non-human species, including monkeys and mice, has indicated that ACE-031 may inhibit muscle atrophy and increase muscular development. Researchers may learn more about the causes of these diseases and maybe find new targets with the help of ACE-031, which has been theorized to block the action of myostatin and activin. 

ACE-031 Peptide: Cellular and Molecular Biology

Studies suggest that researchers may learn more about how myostatin and activin regulate muscle mass and strength by using ACE-031, which is speculated to inhibit their effect. With this knowledge, researchers may create better ways to approach disorders affecting the muscles and possibly enhance the physiological function of many research animals. 

ACE-031 Peptide: Muscular Atrophy

ACE-031 is speculated to stand out as a possible option for disorders characterized by the progressive atrophy of muscle tissue due to its unusual characteristics. There are presently few options for these disorders; however, ACE-031 may provide a new strategy targeting the activin/myostatin pathway. The results may have wider implications for understanding muscular atrophy and wasting illnesses in general, even though this study focused on animals. 

ACE-031 Peptide: Creation and Modification

An immunoglobulin Fc domain is fused to the extracellular domain of a human ActRIIB during the creation and modification of ACE-031. Research indicates that the receptor's potential to bind and neutralize myostatin and activin may be enhanced by this fusion, which produces a stable and soluble version of the receptor. Researchers have optimized the stability, affinity, and potency of ACE-031 thanks to advances in peptide synthesis and protein engineering methods; as a result, it is believed to be an important tool for researching the activin/myostatin pathway. 

ACE-031 Peptide: Future Research Directions

It has been speculated that several interesting avenues may open up as ACE-031 research develops. Among them, scientists must investigate the potential of ACE-031 on different kinds of muscle tissue, find out if it interacts synergistically with other growth factors and signaling pathways, and figure out how to give it to animals in the best manner possible. The findings of this study may shed light on the molecular basis of muscle-wasting illnesses and lead to the creation of new approaches.
 
Buy ACE-031 only if you are a licensed researcher interested in studying the potential of this peptide in contained research environments such as laboratories.
 

References

[i] Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017 Apr;55(4):458-464. doi: 10.1002/mus.25268. Epub 2016 Dec 23. PMID: 27462804.
 
[ii] Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23. doi: 10.1002/mus.23539. Epub 2012 Nov 21. PMID: 23169607.
 
[iii] Gujral DM, Lloyd G, Bhattacharyya S. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab. Breast. 2018 Feb;37:64-71. doi: 10.1016/j.breast.2017.10.010 Epub 2017 Nov 1. PMID: 29101824.
 
[iv] Canter D, Frank GJ, Knapp LE, McLain RW. The safety profile of quinapril: is there a difference among ACE inhibitors? Clin Cardiol. 1990 Jun;13(6 Suppl 7):VII39-42. doi: 10.1002/clc.4960131408. PMID: 2189620.
 
[v] Schütz A, Murek M, Stieglitz LH, Bernasconi C, Vulcu S, Beck J, Raabe A, Schucht P. ACE-inhibitors: a preventive measure for bone flap resorption after autologous cranioplasty? J Neurosurg. 2018 Nov 1:1-8. doi: 10.3171/2018.6.JNS172605. Epub ahead of print. PMID: 30497161.
 
[vi] Gitt AK, Bramlage P, Potthoff SA, Baumgart P, Mahfoud F, Buhck H, Ehmen M, Ouarrak T, Senges J, Schmieder RE; EARLY Registry Group. Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. BMC Cardiovasc Disord. 2016 Mar 8;16:56. doi: 10.1186/s12872-016-0222-6. PMID: 26956148; PMCID: PMC4784379.


Top Stories
Popular Stories


Stories from this Category
Recent Stories